Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Summary

This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.

Timeline

Start

2015-01

Primary completion

2020-12

Completion

2022-07

Publications

• Ou W, Li N, Wang BX, Zhu TF, Shen ZL, Wang T, Chang WG, Chang ZH, Hu XX, Pu Y, Ding LM, Wang SY. Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. EClinicalMedicine. 2023 Feb 3;57:101839. doi: 10.1016/j.eclinm.2023.101839. eCollection 2023 Mar.

Drugs

Indications